Hansen Pharmaceutical
Hansen Pharmaceutical: Innovating nitric oxide technology to combat multi-drug resistant organisms.
Founded
2014Hansen Pharmaceutical: Innovating nitric oxide technology to combat multi-drug resistant organisms.
Founded in 2017, Hansen Pharmaceutical is dedicated to combating multi-drug resistant organisms through innovative nitric oxide technology. Originating from research at Barry University’s Paul & Margaret Brand Research Center, the company has developed proprietary methods to deliver gaseous nitric oxide under pressure, effectively targeting and eliminating resistant pathogens. Hansen Pharmaceutical focuses on healthcare markets where antibiotic resistance poses significant challenges, aiming to provide safer and more effective treatment options.
Key figures associated with Hansen Pharmaceutical include researchers from Barry University who pioneered the initial technology. The company has secured investments from various healthcare-focused venture capital firms, bolstering its research and development efforts. Hansen Pharmaceutical's notable achievements include successful clinical trials demonstrating the efficacy of their nitric oxide delivery system. Their impact is marked by advancements in treating infections that conventional antibiotics fail to address, positioning them as a critical player in the fight against antibiotic resistance.
Companies similar to Hansen Pharmaceutical include SaNOtize, Vast Therapeutics, Handa Pharmaceuticals and NovoBiotic Pharmaceuticals.
Hansen Pharmaceutical was founded in 2014.
Hansen Pharmaceutical's headquarters is located in Miami, FL, US.
Hansen Pharmaceutical's most recent funding round was for $200k (USD) in November 2014.
As of Nov 19, 2014, Hansen Pharmaceutical has raised a total of $200k (USD).
Hansen Pharmaceutical has 6 employees as of Feb 5, 2024.
Handa Pharmaceuticals
handapharma.com
